Within the clinical trials industry, there is a growing consensus about the value of evidence-based research – that is, research that more carefully and methodically takes into account past studies on the same topic – as a way of more efficiently building clinical consensus around particular therapies and to fight what some see as rampant waste and redundancy in research.